WO2001040309A3 - Anti-prostate stem cell antigen (psca) antibody compositions and methods of use - Google Patents

Anti-prostate stem cell antigen (psca) antibody compositions and methods of use Download PDF

Info

Publication number
WO2001040309A3
WO2001040309A3 PCT/US2000/029603 US0029603W WO0140309A3 WO 2001040309 A3 WO2001040309 A3 WO 2001040309A3 US 0029603 W US0029603 W US 0029603W WO 0140309 A3 WO0140309 A3 WO 0140309A3
Authority
WO
WIPO (PCT)
Prior art keywords
psca
antibody
stem cell
antibodies
cell antigen
Prior art date
Application number
PCT/US2000/029603
Other languages
French (fr)
Other versions
WO2001040309A9 (en
WO2001040309A2 (en
Inventor
Brigitte Devaux
Gilbert-Andre Keller
Hartmut Koeppen
Laurence A Lasky
Original Assignee
Genentech Inc
Brigitte Devaux
Keller Gilbert Andre
Hartmut Koeppen
Laurence A Lasky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002387108A priority Critical patent/CA2387108A1/en
Application filed by Genentech Inc, Brigitte Devaux, Keller Gilbert Andre, Hartmut Koeppen, Laurence A Lasky filed Critical Genentech Inc
Priority to IL14911600A priority patent/IL149116A0/en
Priority to AU32618/01A priority patent/AU778199B2/en
Priority to BR0015224-2A priority patent/BR0015224A/en
Priority to EP00991385A priority patent/EP1226177B1/en
Priority to NZ518477A priority patent/NZ518477A/en
Priority to DE60039448T priority patent/DE60039448D1/en
Priority to DK00991385T priority patent/DK1226177T3/en
Priority to JP2001541063A priority patent/JP4028237B2/en
Publication of WO2001040309A2 publication Critical patent/WO2001040309A2/en
Publication of WO2001040309A3 publication Critical patent/WO2001040309A3/en
Priority to NO20021992A priority patent/NO20021992L/en
Publication of WO2001040309A9 publication Critical patent/WO2001040309A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides isolated anti-prostate stem cell antigen (PSCA) antibodies that internalize upon binding to PSCA on a mammalian in vivo. The invention also encompasses compositions comprising an anti-PSCA antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PSCA antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PSCA antibodies. The invention encompasses a method of producing the anti-PSCA antibodies. Other aspects of the invention are a method of killing a PSCA-expressing cancer cell, comprising contacting the cancer cell with an anti-PSCA antibody and a method of alleviating or treating a PSCA-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PSCA antibody to the mammal.
PCT/US2000/029603 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use WO2001040309A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NZ518477A NZ518477A (en) 1999-10-29 2000-10-27 Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo
IL14911600A IL149116A0 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
AU32618/01A AU778199B2 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use
BR0015224-2A BR0015224A (en) 1999-10-29 2000-10-27 Isolated prostatic stem cell (psca) anti-antigen, monoclonal anti-psca antibody, isolated nucleic acid, expression vector, cell, host cell, antibody production method, in vitro method composition to kill a cancer cell that expresses psca , use of an anti-psca monoclonal antibody and industrialized article
EP00991385A EP1226177B1 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
CA002387108A CA2387108A1 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
DE60039448T DE60039448D1 (en) 1999-10-29 2000-10-27 AGAINST PROSTATE-STATE-TEMPORARY (PSCA) ANTIBODIES AND THEIR USE
DK00991385T DK1226177T3 (en) 1999-10-29 2000-10-27 Antibody Compositions for Anti-Prostate Stem Cell Antigen (PSCA) and Applications thereof
JP2001541063A JP4028237B2 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (PSCA) antibody composition and method of use
NO20021992A NO20021992L (en) 1999-10-29 2002-04-26 Anti-prostate stem cell antigen (PSCA) antibody preparation and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16255899P 1999-10-29 1999-10-29
US60/162,558 1999-10-29
US18287200P 2000-02-16 2000-02-16
US60/182,872 2000-02-16

Publications (3)

Publication Number Publication Date
WO2001040309A2 WO2001040309A2 (en) 2001-06-07
WO2001040309A3 true WO2001040309A3 (en) 2001-11-29
WO2001040309A9 WO2001040309A9 (en) 2002-08-15

Family

ID=26858866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029603 WO2001040309A2 (en) 1999-10-29 2000-10-27 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use

Country Status (15)

Country Link
EP (1) EP1226177B1 (en)
JP (1) JP4028237B2 (en)
KR (1) KR100490077B1 (en)
CN (1) CN1413220A (en)
AT (1) ATE400587T1 (en)
AU (1) AU778199B2 (en)
BR (1) BR0015224A (en)
CA (1) CA2387108A1 (en)
DE (1) DE60039448D1 (en)
DK (1) DK1226177T3 (en)
ES (1) ES2309012T3 (en)
IL (1) IL149116A0 (en)
NO (1) NO20021992L (en)
NZ (1) NZ518477A (en)
WO (1) WO2001040309A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100352501C (en) 2001-04-26 2007-12-05 比奥根艾迪克Ma公司 Cripto blocking antibodies and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
KR20040044850A (en) * 2001-09-05 2004-05-31 제넨테크, 인크. Methods for the Identification of Polypeptide Antigens Associated with Disorders Involving Aberrant Cell Proliferation and Compositions Useful for the Treatment of Such Disorders
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7541442B2 (en) 2003-05-30 2009-06-02 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
CN101090729B (en) * 2003-05-30 2014-07-23 艾更斯司股份有限公司 Prostate stem cell antigen (PSCA) variant and its sequence
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
DK3095793T3 (en) 2003-07-28 2020-05-25 Genentech Inc Reduction of leaching of protein A during a protein A affinity chromatography
SI1725249T1 (en) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR100747412B1 (en) * 2003-11-13 2007-08-07 주식회사유한양행 A diagnostic kit for prostatic cancer and prostatic hyperlasi using immunochromatography
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
BRPI0520902B1 (en) * 2004-05-28 2021-11-30 Agensys, Inc MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT BINDS TO PSCA PROTEINS FOR THE DIAGNOSIS OF CANCER, METHOD FOR PRODUCTION THEREOF, HYBRIDOMA, POLYNUCLEOTIDE, VECTOR, COMPOSITION, ASSAY TO DETECT THE PRESENCE OF A PSCA PROTEIN AND METHOD OF DETECTION OF ONE PSCA PROTEIN
PL1753871T3 (en) * 2004-05-28 2016-01-29 Agensys Inc Antibodies and related molecules that bind to psca proteins
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
ES2408704T3 (en) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Crypto binding molecules
RU2007139283A (en) * 2005-03-25 2009-04-27 Гликарт Биотехнологи Аг (Ch) ANTI-BINDING MOLECULES DIRECTED TO MCSP AND HAVING AN INCREASED BINDING OF Fc-RECEPTOR AND EFFECTOR FUNCTION
CN101223191B (en) * 2005-04-14 2012-09-05 阿根西斯公司 Antibodies and related molecules that bind to PSCA proteins
EP1874822A1 (en) * 2005-04-14 2008-01-09 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
KR101566393B1 (en) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 Immunoconjugate formulations
WO2007086932A2 (en) * 2006-01-13 2007-08-02 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
KR20190140090A (en) 2007-07-09 2019-12-18 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
JP6126773B2 (en) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア High affinity anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting and detection
RU2498991C2 (en) 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP3604324B1 (en) 2008-08-14 2024-02-28 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
SG171446A1 (en) 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
KR101764449B1 (en) 2009-09-01 2017-08-02 제넨테크, 인크. Enhanced protein purification through a modified protein a elution
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
PE20130342A1 (en) 2010-04-15 2013-04-20 Spirogen Sarl PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
CN102892791B (en) 2010-05-17 2017-05-17 Emd密理博公司 Stimulus responsive polymers for the purification of biomolecules
RU2614125C2 (en) 2010-05-28 2017-03-22 Дженентек, Инк. Reduction of level of lactate and increasing of production of polypeptide by inhibiting expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Antibody and alaninyl-maitansinol conjugates
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
DE102011118022B4 (en) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antibodies against the prostate-specific stem cell antigen and its use
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
TR201815709T4 (en) 2011-12-22 2018-11-21 Hoffmann La Roche Ion exchange membrane chromatography.
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2831261B1 (en) 2012-03-27 2017-10-18 F. Hoffmann-La Roche AG Method for producing recombinant proteins with low levels of DHNA (1,4-dihydroxy-2-naphthoate)
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
HRP20211641T1 (en) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
PL2766048T3 (en) 2012-10-12 2015-05-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX364328B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates.
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN104994885B (en) 2012-12-19 2017-09-29 基因泰克公司 Method and composition for radiohalogen protein labeling
CN110452242A (en) 2012-12-21 2019-11-15 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EA201690195A1 (en) 2013-08-12 2016-05-31 Дженентек, Инк. ANTIBODY CONJUGATE CONNECTIONS ON THE BASIS OF DIMER 1- (HLORMETHYL) -2,3-DIGYDRO-1H-BENZO [E] INDOL AND METHODS OF APPLICATION AND TREATMENT
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
CN105873614B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112017000142B1 (en) 2014-07-09 2021-08-17 Genentech, Inc METHODS FOR IMPROVING RECOVERY BY DEFROSTING CELL BANKS AND FREEZING CHO CELLS FOR STORAGE, CHO CELL GROUP FOR FREEZING MAMMALS, AND CELL BANK
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AR101844A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTIBODIES AND GENETICALLY MODIFIED CONJUGATES WITH CYSTEINE
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
KR20170101895A (en) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
MX2018011834A (en) 2016-03-29 2019-03-06 Geltor Inc Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1.
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP2020503316A (en) 2016-12-22 2020-01-30 ジェネンテック， インコーポレイテッド Methods and formulations for reducing the reconstitution time of lyophilized polypeptides
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018217926B2 (en) 2017-02-08 2019-10-03 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
KR102442736B1 (en) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 Dosage regime for administration of anti-CD19 ADCs
JP7220203B2 (en) 2017-08-18 2023-02-09 メドイミューン・リミテッド pyrrolobenzodiazepine complex
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3104684A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020009165A1 (en) * 2018-07-03 2020-01-09 味の素株式会社 Modified antibody and method for producing same
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
KR20210074341A (en) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 Methods for membrane gas transfer in high-density bioreactor cultures
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885A (en) 2019-04-12 2022-01-28 格尔托公司 Recombinant elastin and production thereof
KR20220039777A (en) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 Methods for improving protein productivity in fed-batch cell culture
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
JP2023542924A (en) 2020-09-22 2023-10-12 ブリストル－マイヤーズ スクイブ カンパニー Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen
WO2000032752A1 (en) * 1998-12-02 2000-06-08 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof
WO2001005427A1 (en) * 1999-07-20 2001-01-25 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771026B2 (en) * 1998-03-10 2004-03-11 Regents Of The University Of California, The PSCA: prostate stem cell antigen and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen
WO2000032752A1 (en) * 1998-12-02 2000-06-08 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof
WO2001005427A1 (en) * 1999-07-20 2001-01-25 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMARA, NORDINE (1) ET AL: "Monoclonal antibodies against prostate stem cell antigen inhibit prostate cancer tumour formation i SCID mice.", EUROPEAN UROLOGY, (MARCH, 2000) VOL. 37, NO. SUPPL. 2, PP. 105, ABSTRACT 420. PRINT. MEETING INFO.: XVTH CONGRESS OF THE EUROPEAN ASSOCIATION OF UROLOGY BRUSSELS, BELGIUM APRIL 12-15, 2000, XP000999929 *
REITER R E ET AL: "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 17) 95 (4) 1735-40., XP002089381 *
SAFFRAN, DOUGLAS C. ET AL: "Anti- PSCA mAbs inhibit tumor growth and metastasis formation an prolong the survival of mice bearing human prostate cancer xenografts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (FEBRUARY 27, 2001) VOL. 98, NO. 5, PP. 2658-2663. PRINT., XP000999115 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Also Published As

Publication number Publication date
AU3261801A (en) 2001-06-12
IL149116A0 (en) 2002-11-10
CN1413220A (en) 2003-04-23
DK1226177T3 (en) 2008-10-06
CA2387108A1 (en) 2001-06-07
KR100490077B1 (en) 2005-05-17
NO20021992L (en) 2002-06-28
DE60039448D1 (en) 2008-08-21
BR0015224A (en) 2002-07-09
ATE400587T1 (en) 2008-07-15
JP4028237B2 (en) 2007-12-26
AU778199B2 (en) 2004-11-25
EP1226177A2 (en) 2002-07-31
KR20020047303A (en) 2002-06-21
NO20021992D0 (en) 2002-04-26
NZ518477A (en) 2004-10-29
JP2003515330A (en) 2003-05-07
EP1226177B1 (en) 2008-07-09
WO2001040309A9 (en) 2002-08-15
ES2309012T3 (en) 2008-12-16
WO2001040309A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
WO2001040309A3 (en) Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
WO2004101756A3 (en) Ovr110 antibody compositions and methods of use
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
WO2007016590A3 (en) Ovr232v3 antibody compositions and methods of use
WO2006053110A3 (en) Ovr110 antibody compositions and methods of use
WO2006074418A3 (en) Ovr110 antibody compositions and methods of use
EP0253202A3 (en) Novel immunoconjugates and methods for their use in tumor therapy
AU2342897A (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP0220065A3 (en) Trichothecene conjugates
AU563356B2 (en) Conjugate of enzyme and antibody
NZ595450A (en) Antibodies to M-CSF
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
GR3031811T3 (en) Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2004104173A3 (en) Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
ES8801945A1 (en) Monoclonal antibodies against atrial natriuretic peptides.
WO2002012535B1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
WO2005021709A3 (en) Cln101 antibodies
NZ593064A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
AU3546701A (en) Specific monoclonal antibody against terbinafine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2387108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 149116

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 518477

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027005463

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 541063

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000991385

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 32618/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 008172625

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027005463

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000991385

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 518477

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518477

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020027005463

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 32618/01

Country of ref document: AU